Source-grounded facts extracted from Cogent Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cogent Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $97.4 million for the first quarter of 2026 compared to a net loss of $72.0 million for the first quarter o.
“On May 5, 2026, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the three months ended March 31, 2026.”
Cogent Biosciences, Inc. incurred convertible notes of $230,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 1.625% per year maturing November 15, 2031.
“On November 18, 2025, Cogent Biosciences, Inc. (the “Company”) completed its previously-announced public offering (the “Offering”) of $230,000,000 aggregate principal amount of its 1.625% Convertible Senior Notes due 2031”
Cogent Biosciences, Inc. incurred lease obligation with BP THIRD AVENUE LLC maturing seven (7) years and ten (10) months from the Commencement Date.
“On September 5, 2025, Cogent Biosciences, Inc. (“Cogent”) and BP THIRD AVENUE LLC, an affiliate of Boston Properties (the “Landlord”), entered into a lease agreement (the “Lease”)”
Cogent Biosciences, Inc. incurred term loan of $50.0 million with SLR Investment Corp. at 4.75% plus the greater of (i) one-month term SOFR, and (ii) 4.15% per annum maturing June 1, 2030.
“Security Agreement provides for a non-dilutive term loan facility (the “Credit Facility”) of up to an aggregate principal amount of $400.0 million, of which a first tranche of $50.0 million was fully funded on the Closing Date, with future tranches at the Company’s election subject to achievement of milestones consisting of (a) a second tranche of $25.0 million”
Cogent Biosciences, Inc.: Stockholders approved an amendment to the certificate of incorporation to provide for officer exculpation from liability, which was filed and became effective on June 4, 2025 (effective 2025-06-04).
“At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to provide for exculpation from liability for officers of the Company, as described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 22, 2025 (the “Amendment”). On June 4, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect the Amendment, which became effective immediately upon such filing.”
Cogent Biosciences, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $58.3 million.
“Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.